{"filings":[{"id":2613558,"accession_number":"0001193125-26-379348","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2026-09-02T11:30:05+00:00","items":["1.02"],"status":"ready","headline":"MediciNova terminates $30M standby equity purchase agreement with Yorkville","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated SEPA with YA II PN, LTD. effective Sept 8, 2026; no fees or outstanding obligations.","Had right to sell up to $30.0M of common stock; only sold 175,000 shares at $1.39-$1.40 for $0.2M proceeds.","No outstanding borrowings, advance notices, or shares to be issued at termination.","Termination notice delivered Aug 31, 2026; agreement originally dated July 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2337238,"accession_number":"0001193125-26-356146","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2026-08-19T11:30:06+00:00","items":["5.02"],"status":"ready","headline":"MediciNova enters new employment agreements with CEO and CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Yuichi Iwaki: base salary $690,246, bonus target 55% of base.","CMO Dr. Kazuko Matsuda: base salary $540,143, bonus target 40% of base.","Non-CIC severance: 12 months salary plus 12 months COBRA for both executives.","CIC severance: CEO 24 months salary+bonus, CMO 18 months, both 100% equity vesting.","Agreements effective Aug 17, 2026, replace prior arrangements; include 1-yr non-solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1250677,"accession_number":"0001193125-26-281171","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2026-06-24T20:38:44+00:00","items":["5.07"],"status":"ready","headline":"MediciNova shareholders reject proposal to increase authorized shares to 247M at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Hikedi Nagao and Nicole Lemerond elected with ~20.9M and ~21.5M votes for, respectively.","BDO USA ratified as auditor for FY 2026 with 26.7M votes for, 1.9M against.","Proposal to increase authorized common shares from 100M to 247M failed with 22.2M for, 6.4M against; needed majority of outstanding shares.","Adjournment proposal approved with 22.7M for, 5.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102053,"accession_number":"0001193125-26-060232","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MediciNova FY2025 net loss per share $0.24, operating loss $13.3M, cash down to $30.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders $12.0M ($0.24 per share) vs $11.0M ($0.23) in FY2024.","Operating loss widened to $13.3M from $12.7M; net sales (collaboration revenue) totaled $0.41M.","Cash and equivalents fell to $30.8M from $40.4M; shareholders' equity decreased to $41.6M.","No dividend paid; FY2026 guidance withheld due to uncertainty around out-licensing activities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":409657.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118405,"accession_number":"0001193125-25-335917","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MediciNova enters equity distribution agreement for up to $50M at-the-market offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Lucid Capital Markets as sales agent for at-the-market sales of common stock.","Maximum aggregate offering price of $50,000,000 under the Sales Agreement.","Agent compensation set at 3.0% of gross sales price per share sold.","Company may suspend or terminate the agreement at any time; no obligation to sell shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134834,"accession_number":"0001193125-25-170744","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MediciNova enters $30M equity purchase agreement with Yorkville at 97% of VWAP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May sell up to $30M in common stock over 36 months via periodic advances.","Purchase price set at 97% of the lowest of three daily VWAPs during a three-day pricing period.","Fees: $25,000 structuring fee and $375,000 commitment fee paid to Yorkville.","Exchange cap of 9,804,345 shares (19.99% of outstanding) unless stockholder approval or $1.33/share average price met.","Yorkville's beneficial ownership limited to 4.99% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151763,"accession_number":"0000950170-25-087924","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MediciNova annual meeting results: director elected, auditor ratified, say-on-pay approved, 3-year frequency selected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carolyn Beaver elected as Class III director with 22,024,122 votes for, 8,936,487 against, 923,050 abstain.","Ratification of BDO USA as auditor approved: 30,940,507 for, 2,371,963 against, 896,085 abstain.","Advisory vote on executive compensation approved: 21,989,458 for, 8,966,300 against, 927,101 abstain.","Advisory vote on say-on-pay frequency: every 3 years selected with 12,906,546 votes, every 1 year 9,747,859 votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170620,"accession_number":"0001193125-25-051990","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MediciNova updates investor presentation for March 2025 meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished updated slide presentation for use at investor meetings on March 11, 2025.","Presentation covers corporate overview, pipeline status, and business strategy.","No new material financial or operational data were disclosed beyond previously available information.","Presentation reflects current company outlook; no forward-looking guidance was provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220797,"accession_number":"0000950170-24-072461","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MediciNova stockholders re-elect two directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Yuichi Iwaki and Kazuko Matsuda re-elected as Class II directors; votes: 24.3M for, 7.9M against each.","Ratification of BDO USA as independent auditor for FY2024 approved: 27.4M for, 7.5M against, 654K abstain.","Quorum achieved with 35.6M of 49.0M outstanding shares present at June 11, 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220796,"accession_number":"0001193125-24-083356","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MediciNova VP Geoffrey O'Brien resigns as employee, to stay as consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geoffrey O'Brien, VP, retires from full-time employment effective April 2, 2024.","Resignation is voluntary, no disagreement with the Company.","O'Brien will continue as VP on a consulting basis; consulting agreement to be formalized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275249,"accession_number":"0001193125-23-204956","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MediciNova appoints Nicole Lemerond to Board, filling vacancy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lemerond appointed as Class I director, term expiring at 2026 Annual Meeting.","She joins Audit, Compensation, and Nominating Committees immediately.","Granted option to purchase 18,333 shares vesting quarterly through June 30, 2024.","Lemerond is former Managing Partner of NV Capital (2010-2022) with 25+ years in healthcare finance.","No family relationships or material transactions with existing directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292708,"accession_number":"0001193125-23-172585","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MediciNova receives two Nasdaq deficiency notices for board and audit committee independence","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Audit Committee Notice on June 15, 2023 due to committee having two independent members instead of three.","Received Independent Board Notice on June 22, 2023 for having only two independent directors out of five board seats.","Cure period: until the earlier of next annual meeting or June 13, 2024 (or Dec 11, 2023 if meeting before then).","Company plans to appoint an additional independent director; no immediate impact on stock listing or trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292707,"accession_number":"0000950170-23-027823","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect director, ratify auditor, approve 2023 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hideki Nagao elected Class I director with 19.7M for, 7.5M against, 1.4M abstain, 2.7M broker non-vote.","BDO USA, LLP ratified as independent auditor for fiscal 2023: 27.8M for, 2.4M against, 1.1M abstain.","2023 Equity Incentive Plan approved: 19.2M for, 7.9M against, 1.5M abstain, 2.7M broker non-vote.","Meeting held June 13, 2023; 31.3M shares voted of 49.0M outstanding (quorum present)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292706,"accession_number":"0001193125-23-118572","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MediciNova director Jeff Himawan to not stand for re-election due to health reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jeff Himawan notified Board he will not stand for re-election as Class I director at 2023 annual meeting.","Decision solely due to personal health reasons; no disagreement with Company operations, policies, or practices.","His term ends at the Annual Meeting; seat will remain vacant until filled per Company Bylaws.","Company thanks Dr. Himawan for his leadership and service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366250,"accession_number":"0001193125-22-177628","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MediciNova CFO Douglas Paulin resigns; Jason J. Kruger appointed as new CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective June 16, 2022, Douglas Paulin resigned as CFO; Jason J. Kruger appointed as CFO and Principal Financial Officer.","Kruger, age 45, is president/founder of Signature Analytics; previously Senior Manager at Deloitte & Touche.","Kruger will serve under an amended services agreement with Signature Analytics with pre-approved hourly rates; term expires Aug 1, 2022 with annual renewals.","No family relationships or material transactions between Kruger and the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366249,"accession_number":"0001564590-22-023341","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MediciNova stockholders elect director, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carolyn Beaver elected Class III director with 22.2M for, 4.6M against, 0.8M abstain (3.2M broker non-vote).","BDO USA LLP ratified as independent auditor for FY2022: 25.6M for, 2.5M against, 2.7M abstain.","Advisory vote on named executive officer compensation approved: 19.2M for, 5.4M against, 3.0M abstain.","Quorum present: 30,788,491 shares (~62.8% of 49,043,246 outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366248,"accession_number":"0001193125-22-095275","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2022-04-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MediciNova may receive portion of Genzyme's damages from Novartis Zolgensma patent suit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Genzyme filed First Amended Complaint on Feb 23, 2022 in Delaware court adding U.S. Patent No. 9,051,542 against Novartis over Zolgensma.","MediciNova, as successor to Avigen, assigned patents to Genzyme in 2005 and may receive a portion of any damages recovered.","Lawsuit targets unauthorized use of rAAV vectors for gene therapy drug Zolgensma.","No guarantee of payment; contingent on Genzyme's recovery via settlement or judgment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422592,"accession_number":"0001193125-21-233293","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Edward Stepanow resigns; Douglas Paulin appointed CFO effective August 1, 2021 via outsourced services agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward Stepanow resigned as CFO effective July 31, 2021; no reason given.","Douglas Paulin (CPA) appointed CFO effective August 1, 2021, through a services agreement with Signature Analytics.","Services agreement: hourly rate range for CFO services $270-$350/hr; initial term one year with automatic renewal.","Paulin joined Signature Analytics in July 2020; previously Head of Finance at AerNos and Director of EMEA Finance at Sonos.","No family relationships or material interests between Paulin and other officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422591,"accession_number":"0001193125-21-222985","cik":1226616,"company_name":"MEDICINOVA INC","ticker":"MNOV","form_type":"8-K","filed_at":"2021-07-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MediciNova signs 5-year lease for La Jolla HQ; base rent $14,464/month","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lease term of 60 months from Feb 1, 2022 to Jan 31, 2027, for 4,383 sq ft at 4275 Executive Square, La Jolla.","Monthly base rent starts at $14,463.90 (Year 1), escalating to $17,269.02 (Year 5); 3 months' rent abated ($43,391.70 total) from Mar to May 2022.","Security deposit of $47,923.72, with $14,463.90 reductions in Feb 2023 and Feb 2024 if no default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":66202576.69924811,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}